125 related articles for article (PubMed ID: 33863777)
1. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Murai Y; Jo U; Murai J; Jenkins LM; Huang SN; Chakka S; Chen L; Cheng K; Fukuda S; Takebe N; Pommier Y
Cancer Res; 2021 Jun; 81(11):3067-3078. PubMed ID: 33863777
[TBL] [Abstract][Full Text] [Related]
2. GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.
Liu G; Yu J; Wu R; Shi L; Zhang X; Zhang W; Zhong X; Wang Y; Li H; Shen Y; Wu C; Yu R; Niu M; Liu X
Cell Death Dis; 2021 Jul; 12(8):733. PubMed ID: 34301924
[TBL] [Abstract][Full Text] [Related]
3. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y; Jo U; Kumar S; Sun NY; Elloumi F; Thomas A; Roper N; Varghese DG; Takebe N; Zhang X; Ceribelli M; Holland DO; Beck E; Itkin Z; McKnight C; Wilson KM; Travers J; Klumpp-Thomas C; Thomas CJ; Hoang CD; Hernandez JM; Del Rivero J; Pommier Y
Cancer Res Commun; 2024 Mar; 4(3):834-848. PubMed ID: 38451783
[TBL] [Abstract][Full Text] [Related]
4. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Murai J; Thomas A; Miettinen M; Pommier Y
Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
Cancer Treat Rev; 2024 Jul; 128():102768. PubMed ID: 38797062
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer.
Majeed S; Aparnathi MK; Nixon KCJ; Venkatasubramanian V; Rahman F; Song L; Weiss J; Barayan R; Sugumar V; Barghout SH; Pearson JD; Bremner R; Schimmer AD; Tsao MS; Liu G; Lok BH
Clin Cancer Res; 2022 May; 28(9):1966-1978. PubMed ID: 35165102
[TBL] [Abstract][Full Text] [Related]
7. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
[TBL] [Abstract][Full Text] [Related]
8. Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication.
Murai J; Ceribelli M; Fu H; Redon CE; Jo U; Murai Y; Aladjem MI; Thomas CJ; Pommier Y
Mol Cancer Ther; 2023 Aug; 22(8):985-995. PubMed ID: 37216280
[TBL] [Abstract][Full Text] [Related]
9. SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing.
Mezzadra R; de Bruijn M; Jae LT; Gomez-Eerland R; Duursma A; Scheeren FA; Brummelkamp TR; Schumacher TN
PLoS One; 2019; 14(2):e0212053. PubMed ID: 30753225
[TBL] [Abstract][Full Text] [Related]
10. Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.
Jacob S; Turner TH; Cai J; Floros KV; Yu AK; Coon CM; Khatri R; Alzubi MA; Jakubik CT; Bouck YM; Puchalapalli M; Shende M; Dozmorov MG; Boikos SA; Hu B; Harrell JC; Benes CH; Koblinski JE; Costa C; Faber AC
PNAS Nexus; 2022 Nov; 1(5):pgac232. PubMed ID: 36712364
[TBL] [Abstract][Full Text] [Related]
11. Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway.
Murai Y; Jo U; Murai J; Fukuda S; Takebe N; Pommier Y
iScience; 2021 Oct; 24(10):103173. PubMed ID: 34693224
[TBL] [Abstract][Full Text] [Related]
12. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
Kaur S; Schwartz AL; Jordan DG; Soto-Pantoja DR; Kuo B; Elkahloun AG; Mathews Griner L; Thomas CJ; Ferrer M; Thomas A; Tang SW; Rajapakse VN; Pommier Y; Roberts DD
Front Oncol; 2019; 9():994. PubMed ID: 31632920
[TBL] [Abstract][Full Text] [Related]
13. Modulation of SLFN11 induces changes in DNA Damage response in breast cancer.
Raynaud CM; Ahmed EI; Jabeen A; Sanchez A; Sherif S; Carneiro-Lobo TC; Awad A; Awartani D; Naik A; Thomas R; Decock J; Zoppoli G; Bedongnetti D; Hendrickx WRL
Cancer Cell Int; 2023 Nov; 23(1):291. PubMed ID: 38001424
[TBL] [Abstract][Full Text] [Related]
14. Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response.
Alvi E; Mochizuki AL; Katsuki Y; Ogawa M; Qi F; Okamoto Y; Takata M; Mu A
Commun Biol; 2023 Oct; 6(1):1038. PubMed ID: 37833372
[TBL] [Abstract][Full Text] [Related]
15. The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13.
Fujiwara K; Maekawa M; Iimori Y; Ogawa A; Urano T; Kono N; Takeda H; Higashiyama S; Arita M; Murai J
iScience; 2023 Dec; 26(12):108529. PubMed ID: 38125019
[TBL] [Abstract][Full Text] [Related]
16. Structural and biochemical characterization of Schlafen11 N-terminal domain.
Hou P; Hao W; Qin B; Li M; Zhao R; Cui S
Nucleic Acids Res; 2023 Jul; 51(13):7053-7070. PubMed ID: 37293979
[TBL] [Abstract][Full Text] [Related]
17. The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML.
Barghout SH; Schimmer AD
Oncotarget; 2018 Sep; 9(76):34198-34199. PubMed ID: 30344936
[No Abstract] [Full Text] [Related]
18. Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?
Inno A; Stagno A; Gori S
Transl Lung Cancer Res; 2018 Dec; 7(Suppl 4):S341-S345. PubMed ID: 30705850
[No Abstract] [Full Text] [Related]
19. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Jo U; Senatorov IS; Zimmermann A; Saha LK; Murai Y; Kim SH; Rajapakse VN; Elloumi F; Takahashi N; Schultz CW; Thomas A; Zenke FT; Pommier Y
Mol Cancer Ther; 2021 Aug; 20(8):1431-1441. PubMed ID: 34045232
[TBL] [Abstract][Full Text] [Related]
20. Parp1 hyperactivity couples DNA breaks to aberrant neuronal calcium signalling and lethal seizures.
Komulainen E; Badman J; Rey S; Rulten S; Ju L; Fennell K; Kalasova I; Ilievova K; McKinnon PJ; Hanzlikova H; Staras K; Caldecott KW
EMBO Rep; 2021 May; 22(5):e51851. PubMed ID: 33932076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
